Trial Profile

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MAR-001 (Primary)
Indications Hypertriglyceridaemia
Focus Adverse reactions
Sponsors Marea Therapeutics

Most Recent Events

16 May 2025 Results presented in the Marea Therapeutics Media Release
16 May 2025 According to Marea Therapeutics media release, data from Phase 2a were published in The Lancet
07 May 2025 According to Marea Therapeutics media release, phase IIa results were presented at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com